Print

Psoriasis Associated With Other Major Medical Conditions

EMBARGOED FOR RELEASE: 3 P.M. (CT), WEDNESDAY, AUGUST 7, 2013

Media Advisory: To contact corresponding author Joel M. Gelfand, M.D., M.S.C.E., call Kim Menard at 215-662-6183 or email Kim.Menard@uphs.upenn.edu.


CHICAGO – Psoriasis is associated with higher rates of other diseases including chronic pulmonary disease, diabetes mellitus, mild liver disease and myocardial infarction (heart attack), according to a report published Online First by JAMA Dermatology, a JAMA Network publication.

 

Psoriasis is a common chronic inflammatory disease, but there is a gap in knowledge about how psoriasis severity may be related to the prevalence of other major medical conditions, Howa Yeung, B.S., of the University of Pennsylvania, Philadelphia, and colleagues write in the study background.

 

Researchers examined patient data from United Kingdom-based electronic medical records. Their analysis included 9,035 patients ages 25 to 64 years with psoriasis and 90,350 age- and practice-matched patients without psoriasis. Psoriasis severity was determined in 8,726 patients (96.6 percent), among whom 4,523 (51.8 percent) had mild, 3,122 (35.8 percent) had moderate and 1,081 (12.4 percent) had severe psoriasis.

 

Psoriasis overall was associated with a higher prevalence of chronic pulmonary disease (adjusted odds ratio, 1.08), diabetes mellitus (1.22), diabetes with systemic complications (1.34), mild liver disease (1.41), myocardial infarction (1.34) peptic ulcer disease (1.27), peripheral vascular disease (1.38) renal disease (1.28) and rheumatologic disease (2.04), the study results indicate.

 

“The burdens of overall medical comorbidity and of specific comorbid diseases increase with increasing disease severity among patients with psoriasis. Physicians should be aware of these associations in providing comprehensive care to patients with psoriasis, especially those presenting with more severe disease,” the authors conclude.

(JAMA Dermatology. Published online August 7, 2013. doi:10.1001/jamadermatol.2013.5015. Available pre-embargo to the media at http://media.jamanetwork.com.)

 

Editor’s Note: Authors made a conflict of interest disclosures. This study was supported by National Institutes of Health grants, a National Psoriasis Foundation Fellowship and an American College of Rheumatology Investigator Award. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.